Your reading list

$25.5m verdict against Aetna. “New, simpler economic models” for PBMs Cost of ageism: $63 billion. What is the FDA doing about opioids? Value-based drug pricing in Michigan’s Medicaid program. Leading health care moneymakers. HRRP works in California. Access to pharmaceuticals in China.

Friday Links

Building bridges. Stents, the Shape Memory Effect and Superelasticity. Does digital lead to poor surgeons?W Will a drug work for you?  Can 23andMe really help answer this question? Utah-Mexico new medical tourism connection. Doing business. ACA reduced insurance disparities. FDA guidance on meta-analysis.

Links

Treating cancer: the promise of IO combination therapy. FDA on developing drugs for rare diseases. CEA: v-thresholds vs. k-thresholds. Pharma fights back against PBMs by slashing prices? Debt to double by 2050? Sex workers over-report use of condoms. Are concerns over FDA’s “Pre-Cert for Software Pilot Program” justified? Moneyball in Medicare.

Healthcare Economist on President Trump’s plan to lower Medicare drug prices

A recent report from Assistant Secretary for Planning and Evaluation (ASPE) found that for about 30 physician administered drugs, prices are 8 times as high as those charged in other developed countries. To address the high prices, President Trump unveiled a three-part plan to reduce drug prices.  Under the “international pricing index” proposal, U.S. drug…

AMA and the adoption of digital medicine

There is a lot of hype about digital medicine.  Though the definition of what digitla medicine mans varies, many digital devices are able to monitor patient physiology, medication adherence, or other behavior and communicate that with the patient as well as their provider team. One key barrier to having the provider team actually use these…

MacArthur “Genius” Fellows announced

This year’s MacArthur “Genius” Fellows were announced today.  While there is a great diversity of amazing individuals receiving the grants, I will focus on those related to the health care space: Amy Finkelstein: health economist, at MIT, who is formulating robust experimental designs that provide data-driven guidance for innovations in health care theory, policy, and delivery…